胸膜接触降低接受立体定向体部放疗的临床T1N0M0肺癌患者生存
该回顾性研究纳入2006至2017年接受立体定向体部放疗、原发肿瘤直径≤4 cm且N0M0的非小细胞肺癌患者386例,分析肿瘤与胸膜关系对疗效的影响。在T1-size(0.1-3.0 cm)患者中,胸膜接触组3年病因特异性死亡率17.6% vs 无接触组6.6%(p<0.01),总生存58.2% vs 77.6%(p<0.01);多因素分析胸膜接触与病因特异性死亡(HR 1.96)和总生存(HR 1.59)相关。结论认为临床T1N0M0肺癌胸膜接触与显著更差的生存相关。
要点
- T1-size肿瘤胸膜接触组3年病因特异性死亡率17.6% vs 无接触组6.6%(p<0.01)。
- T1-size肿瘤胸膜接触组3年总生存58.2% vs 无接触组77.6%(p<0.01)。
- 多因素分析胸膜接触与病因特异性死亡(HR 1.96)和总生存(HR 1.59)相关。
核心结论
- 临床T1N0M0肺癌患者的胸膜接触与显著更差的生存相关。
研究设计与样本
- 回顾性研究,纳入2006至2017年连续接受立体定向体部放疗、原发肿瘤直径≤4 cm且N0M0的非小细胞肺癌患者386例。
- T1-size组323例(肿瘤0.1-3.0 cm),T2a-size组63例(肿瘤3.1-4.0 cm)。
- 分析肿瘤与胸膜关系对治疗结局的影响。
主要发现
- T1-size患者中,胸膜接触120例、胸膜凹陷134例、胸膜增厚23例。
- T1-size胸膜接触组3年病因特异性死亡率17.6%(95%CI 10.7-25.9%)vs 无接触组6.6%(95%CI 3.5-11.1%),p<0.01。
- T1-size胸膜接触组3年总生存58.2%(95%CI 47.6-67.5%)vs 无接触组77.6%(95%CI 70.5-83.2%),p<0.01。
- 局部复发、区域复发、胸膜腔复发和远处转移与更差的病因特异性死亡率和总生存相关。
- 多因素分析胸膜接触与病因特异性死亡(HR 1.96;95%CI 1.09-3.52;p=0.03)和总生存(HR 1.59;95%CI 1.08-2.34;p=0.02)相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical staging, as used for patients treated with stereotactic body radiotherapy (SBRT) for early-stage lung cancer, inadequately accounts for pleural invasion, which is a pathologic criteria. Considering the current situation, we analyzed effects of relationships between tumors and the pleura on treatment outcomes of SBRT for early-stage lung cancer. MATERIALS AND METHODS: Among consecutive patients treated with SBRT between 2006 and 2017, we retrospectively identified non-small cell lung cancer patients with primary tumor diameters ≤4 cm and N0M0. The relationships between tumors and the pleura were investigated. The effects of these findings on treatment outcomes were analyzed. RESULTS: We identified 386 patients which met the inclusion criteria. Among these patients, 323 patients were with tumors of 0.1-3.0 cm (T1-size), and 63 patients were with tumors of 3.1-4.0 cm (T2a-size). Among patients with T1-size tumors, 120, 134, and 23 had findings of pleural contact, pleural indentation, and pleural thickening, respectively. When we divided T1-size patients into 2 groups based on pleural contact (contact- or contact+), the 3-year cause-specific mortality and overall survival in patients with T1-size & contact+ were significantly worse than those in patients with T1-size & contact- (17.6% (95% confidence interval (CI), 10.7-25.9%) vs. 6.6% (95% CI, 3.5-11.1%), p < 0.01), and 58.2% (95% CI, 47.6-67.5%) vs. 77.6% (95% CI, 70.5-83.2%), p < 0.01). Local recurrence, regional recurrence, pleural cavity recurrence, and distant metastasis were associated with worse cause-specific mortality and overall survival. On multivariate analysis, pleural contact was associated with cause-specific mortality (hazard ratio (HR), 1.96; 95% CI, 1.09-3.52; p = 0.03) and overall survival (HR, 1.59; 95% CI, 1.08-2.34; p = 0.02). CONCLUSION: Pleural contact in clinical T1N0M0 lung cancer patients was associated with significantly worse survivals.
引用
- Eriguchi T, Takeda A, Tsurugai Y, et al. Pleural contact decreases survival in clinical T1N0M0 lung cancer patients undergoing SBRT. Radiother Oncol. 2019. PMID: 31005215. doi:10.1016/j.radonc.2019.02.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。